СЛОВО,Abstract:,Infections,in,childhood,play,an,essential,role,the,pathogenesis,of,cognitive,and,psycho-emotional,disorders.,One,possible,mechanisms,these,impairments,is,changes,functional,properties,NMDA,AMPA,glutamate,receptors,brain.,We,suggest,that,bacterial,infections,during,early,life,"period,",which,critical,for,excitatory,synapse,"maturation,",can,affect,subunit,composition,receptors.,In,present,"study,",we,investigated,effect,repetitive,lipopolysaccharide,(LPS),intraperitoneal,(i.p.),administration,(25 μg/kg/day,on,"P14,","16,","18),",mimicking,infectious,"disease,",expression,subunits,young,rats.,revealed,a,substantial,decrease,GluN2B,hippocampus,at,P23,using,Western,blot,analysis,real-time,polymerase,chain,reaction,assay.,Moderate,were,also,found,"GluN1,","GluN2A,",GluA1,mRNA,expression.,The,LPS-treated,rats,exhibited,decreased,exploratory,locomotor,activity,open,field,test,impairment,spatial,learning,Morris,water,maze.,Behavioral,accompanied,by,significant,reduction,long-term,hippocampal,synaptic,potentiation.,Our,data,indicate,LPS-treatment,period,maturation,alters,ionotropic,receptor,gene,"expression,",disturbs,"plasticity,","behavior.
",Prolonged,exposure,to,manganese,(Mn),may,lead,toxic,effects,central,nervous,system,(CNS).,underlying,neuronal,death,from,Mn,are,not,well,understood,but,undoubtedly,involve,inflammatory,processes.,aim,this,study,was,explore,long-lasting,intranasal,focusing,processes,catecholamine,"(dopamine,",norepinephrine),levels,striatum,hippocampus.,It,instillation,MnCl2,solution,once,day,90,days,leads,impaired,movement,gait.,observed,concentration,increased,(by,30,%),220,"%),",dopamine,(24,DOPAC,(35,reduced,"striatum,",(190,(220,with,simultaneously,norepinephrine,(30,Observation,cytokine,both,assayed,cytokines,(IL-1β,TNF-α),There,3-fold,increase,IBA-1,"mRNA,",2-fold,NFκB,dramatic,IkB,striatum.,Taken,"together,",high,dose,induces,neuroinﬂammation,neurotransmission,"disturbance,",specific,each,studied,brain,"region.
",Shortly,after,syphilis,appeared,Europe,time,Columbus’,voyage,New,"World,",big,"pox,",as,it,often,"known,",became,serious,issue,Russia,"diagnosis,","treatment,",prevention.,Members,Russian,royal,family,made,aware,disease,adolescence,onward.,Czar,Peter,Great,had,many,sexual,contacts,could,have,contracted,any,number,sexually,transmitted,diseases,(STDs),quite,common,his,era.,"Nevertheless,",contributions,analyzed,available,sources,contemporary,"doctors,",later,medical,"analyses,",reveal,no,evidence,he,or,other,STD.,Most,"likely,",died,acute,renal,failure,due,urinary,tract,"obstruction.
",Upper,respiratory,world's,most,disease.,etiologic,agents,behind,upper,(URTIs),"are,","fact,",diverse,set,pathogens,such,"influenza,","parainfluenza,","adenovirus,","rhinovirus,",others.,More,than,200,known,be,involved.,Differential,diagnosis,viral,sometimes,complicated,their,diversity,similarity,clinical,presentation.,This,work,devoted,development,method,enables,simultaneous,detection,six,URTI,pathogens:,IAV;,IBV;,RSV;,hAdV;,hPIV2;,hPIV3.,Antibody,microarray,technology,utilized,accomplish,analysis.,preparation,protein,microchip,"creation,","produced,","characterized,",selected,approximately,50,monoclonal,antibodies;,aforementioned,"pathogens,",optimal,antibody,pair,selected.,A,"created,",its,core,working,conditions,optimized.,With,balance,between,convenience,maximal,assay,sensitivity,"mind,",one-step,approach,developed,accomplishing,ELISA-like,“sandwich”,interaction,manufactured,(antibody,microarray).,Reference,strains,used,establish,lower,limits,(LoD),For,"IAV,",LoD,0.25 ng/ml,total,protein.,"viruses,",ranged,1,2 ng/ml,These,slightly,better,those,standard,"ELISA,",inferior,PCR.,"Overall,",believe,good,alternative,existing,"methods,",allowing,relatively,quick,"(overnight),","inexpensive,",screening,several,pathogens.,design,conducive,further,"development,",panel,expanded,include,"members.
",fullerene,"members,","C60,",has,potential,application,various,fields,biomedicine,including,reactive,oxygen,species,(ROS),scavenging,"activity,",inhibiting,tumours,inactivating,viruses,"bacteria,",elaboration,diagnostic,targeted,drug,delivery,tools.,"However,",hydrophobicity,molecule,impedes,practical,"use,",therefore,actuality,research,functionalisation,fullerenes,leading,amphiphilic,derivatives,remains,important.,"work,",water-soluble,carboxylated,derivative,C60[C(COOH)2]3,studied.,Extensive,biomedical,investigation,"compound,","namely,",binding,human,serum,albumin,"(HSA),",radical,diphenylpicrylhydrazyl,(DPPH),"radical,",photodynamic,"properties,",cytotoxicity,embryonic,kidney,(HEK293),cell,"line,",erythrocytes',"haemolysis,",platelet,"aggregation,",genotoxicity,peripheral,mononuclear,cells,(PBMC),conducted.,"Moreover,",dynamic,structural,characteristics,C60[C(COOH)2]3–H2O,binary,obtained,molecular,(MD),"method,",size,distribution,associates,"measured.
","Aims
",our,single-center,retrospective,evaluated,whether,level,different,checkpoint,molecules,bone,marrow,biopsies,course,patients,myelodysplastic,syndrome,"(MDS).
",Methods,"results
",consecutive,cohort,55,MDS,treated,center,2003,2018,technique,able,detect,following,antigens:,"PD-1,","PD-L1,","PD-L2,","LAG-3,","Gal-9,","TIM-3,",CD80.,association,3-year,overall,relapse-free,survival,time-to-progression,analyzed.,Intensive,TIM-3,100%,cases.,"Also,","cases,",moderate,Gal-9,observed.,follow-up,progression,seen,72.9%,CD80,52.1%,low,(p=0.04).,CTLA4,ligands,co-expressed,majority,patients.,General,ligand,associated,incidence,progression:,67.2%,"progressed,",while,group,only,33.3%,cases,(p=0.059).,"CD80,","TIM3,",blasts,risk,according,IPSS,IPSS-R,"scales.
","Conclusions
",preliminary,underlined,heterogeneous,immune,warrants,studies,define,heterogeneity,develop,treatment,"approaches.
","Background
",COVID-19,pandemic,broadly,disrupted,non-invasive,stimulation,(NIBS).,rapid,onset,societal,disruption,evolving,regulatory,restrictions,allowed,systematic,planning,how,continue,throughout,restarted,abated.,urgency,provide,NIBS,intervention,neurological,mental,health,"indications,",catalyst,fundamental,"research,",dampened,parallel,efforts,address,life-threatening,aspects,COVID-19;,rather,need,heightened,mitigate,consequences,related,"COVID-19.
","Objective
",To,facilitate,re-establishment,access,services,operations,current,future,"outbreaks,",discuss,framework,balancing,importance,safety,"considerations,",addressing,needs,all,stakeholders.,focus,Transcranial,Magnetic,Stimulation,(TMS),intensity,transcranial,Electrical,(tES),-,Direct,Current,(tDCS),Alternating,"(tACS).
","Methods
",consensus,paper,provides,guidelines,practices,managing,reopening,clinics,laboratories,through,immediate,ongoing,stages,COVID-19.,document,reflects,experts,domain-relevant,expertise,spanning,"technology,","services,",basic,–,international,perspective.,outline,"aspects,","resources,","optimization,",accommodations,"demographics.
","Results
",model,based,three,phases,(early,"impact,","practices,",preparation),11-step,checklist,(spanning,removing,streamlining,in-person,"protocols,",incorporating,"telemedicine,",COVID-19-associated,adverse,events),proposed.,Recommendations,implementing,social,distancing,sterilization,"equipment,",considerations,positive,populations,"comorbidities,",regarding,resource,era,outlined.,specifically,(sub-)populations,"pediatric,","stroke,","addiction,",elderly.,Numerous,case-examples,across,world,"described.
","Conclusion
","evident,","urgent,",maintain,"pandemic,",anticipating,waves,mind.,proposed,robust,structured,strategy,aims,anticipated,challenges,maintaining,scientific,rigor,"risk.
",Background:,Data,genetic,markers,determine,prognosis,multiple,sclerosis,(MS),still,limited.,galanin,polymorphism,rs948854,MS,been,demonstrated,earlier.,Objectives:,confirm,earlier,findings,distinct,previously,"patients,",characterized,one,candidates,stratification,MS.,Methods:,assess,rate,"progression,",severity,score,(MSSS),Age,Related,Multiple,Sclerosis,Severity,(ARMSS),"used,",along,Progression,Index,(PI).,Results:,minor,allele,"revealed,",confirming,findings.,An,proportion,MSSS > 5,(high,progression),among,G,carriers,(genotypes,AG,GG),compared,AA,genotype.,"Furthermore,",age,correlated,MSSS,value,late,(>30,years).,Conclusion:,"Collectively,",support,contribution,"MS.
","Summary
","Purpose
",describe,analyze,patient,recurrent,idiopathic,exudative,polymorphous,vitelliform,maculopathy,"(AEPVM),",followed,"detail,",propose,"algorithm.
","Design
",Retrospective,observational,"analysis.
","Patient
",adult,male,diagnosed,AEPVM,who,two,relapses,12-month,eight,years,initial,"onset.
",Review,"charts,",multimodal,"imaging,",electrophysiology,repeatedly,underwent,complete,ophthalmic,"examinations,",best-corrected,visual,acuity,testing,"(BCVA),",slit-lamp,fundus,examinations;,digital,"photography,",time-domain,optical,coherence,tomography,(OCT),2009,(Stratus,"OCT,",Carl,Zeiss,"Meditec,",USA),spectral-domain,OCT,2017–2018,"(Spectralis-OCT,",Heidelberg,"Engineering,","Germany),",together,autofluorescence,"(FAF),",fluorescein,angiography,"(FA),",indocyanine,green,"(ICGA),",HRA2,(Heidelberg,Germany);,microperimetry,(MP-1,"microperimeter,","Nidek,",Japan).,Laser,flare,photometry,(Kowa,"FM-600,",Japan),"performed.
",Main,outcome,"measures
",Clinical,features,"AEPVM,",algorithm,rare,"cases.
",Case,report,25-year-old,Caucasian,typical,serous,neuroepithelial,detachment,irregular,retinal,"elevations,",ophthalmoscopically,resembling,"folds,",subsequent,subretinal,accumulation,characteristic,yellow–white,deposits.,Features,case,rarely,"described,",even,yet,"reported,",indocyanine-,fluorescein-negative,intraretinal,cystic,"changes,",optic,disc,hyperfluorescence,"FA,",elevations,choroidal,"thickness,",lack,"recovery,",very,slow,anatomical,improvement,relapses.,Bimonthly,evaluation,SD-OCT,informative,demonstrating,evolution,pathological,"signs.
",chronic,condition,uncertain,outcomes.,variable,presentations,depending,stage,manifestations,imaging,pathologic,process,overlap.,Patients,should,occurs,"slowly,",if,all.,recommended,"ABSTRACT
",Allogeneic,hematopoietic,transplantation,(HCT),high-risk,T,lymphoblastic,leukemia,(T-ALL).,without,HLA-identical,"donor,",haploidentical,(haplo-),HCT,becoming,source,stem,donation.,scarce,predictive,factors,setting.,identified,122,adults,(20%,female;,median,"age,",31,years;,"range,",18,68,years),T-ALL,haplo-HCT,post-transplantation,cyclophosphamide,(ptCy),2010,2017.,duration,living,23,months.,2-year,incidences,relapse,nonrelapse,mortality,45%,"21%,",respectively.,leukemia-free,"(LFS),","(OS),",graft-versus-host,(GRFS),"34%,","42%,","27%,",LFS,OS,highly,influenced,status,"transplantation,",being,49%,"55%,","respectively,",first,remission,(CR1);,34%,"50%,",second,CR,(CR2);,8%,"12%,",active,On,multivariate,"analysis,",OS.,Transplantation,CR2,negatively,affected,"LFS,",whereas,"conclusion,",ptCy,produced,encouraging,results,challenging,particularly,when,performed,CR.,Despite,limitation,small,sample,"size,",type,"conditioning,",calling,into,question,body,irradiation-based,myeloablative,conditioning,"setting.
","HIV,",heavy,"drinking,",smoking,pro-inflammatory,coronary,heart,(CHD).,Interventions,reduce,alcohol,"smoking,",HIV-positive,people,"inflammation,",CHD,risk.,Varenicline,cytisine,proven,therapies,cessation,consumption.,comparative,efficacy,varenicline,consumption,"tested,",nor,effectiveness,reported,"smoking.
",describes,protocol,Studying,Partial,agonists,Ethanol,Tobacco,Elimination,Russians,HIV,(St,PETER,"HIV),",four-arm,parallel-group,randomized,controlled,trial,comparing,"varenicline,","cytisine,",nicotine,replacement,therapy,"(NRT).
",recruiting,four,hundred,drinking,smokers,interested,cutting,down,and/or,tobacco,St.,"Petersburg,",Russia.,Participants,randomly,assigned,receive,either,varenicline + NRT,"placebo,",placebo + active,"NRT,",cytisine + NRT,NRT.,All,participants,evidence-based,counseling,"medication,",placebo.,Outcomes,are:,1),%,past,month,(primary,months),craving;,2),cigarettes,per,3,7-day,point,prevalence,abstinence,and;,3),"risk,",St,addresses,paucity,guide,"smokers.
",Here,evaluate,mast,infection,influenza,A/H5N1,virus,immunized,mice.,CBA,mice,intramuscularly,formalin-inactivated,A/Vietnam/1194/2004,(H5N1)NIBRG-14,(H5N1).,Serum,samples,"7,","12,","14,",21,immunization.,At,infected,intranasally,A/Indonesia/5/2005,(H5N1)IDCDC-RG2,(H5N1),half,animals,receiving,mixture,antihistamines.,67%,vaccinated,protected,lethality,43%,PBS-immunized,group.,Administration,antihistamines,up,85%–95%.,Immunohistochemical,examination,CD117,staining,lungs,larger,quantity,activated,mock-immunized,histamine,blood.,experimental,involvement,they,produce,incomplete,formation,response,vaccination,mismatch,vaccine,"viruses.
",Gestational,methylazoxymethanol,acetate,(MAM),produces,offspring,phenotype,relevant,"schizophrenia,",positive-,negative-like,"symptoms,","deficits,",dopaminergic,"dysfunction,",abnormalities.,show,prenatally,MAM,gestational,17,display,D3,(D3),prefrontal,cortex,"(PFC),",nucleus,"accumbens,",D2,(D2),exclusively,PFC.,change,blood,perfusion,circle,Willis,"hippocampus,",paralleled,enlargement,lateral,"ventricles,",detected,magnetic,resonance,(MRI),techniques.,Peripubertal,non-euphoric,phytocannabinoid,cannabidiol,(30 mg/kg),postnatal,(PND),19,PND,39,reverse,exposed,rats:,i),up-regulation,(only,partially,prevented,haloperidol,0.6 mg/kg/day);,ii),regional,flow,Molecular,modelling,predicted,bind,preferentially,"receptor,",where,act,partial,agonist,conformation,"ionic-lock,",conserved,GPCRs.,"summary,",demonstrate,altered,model;,however,transcript,likely,suggesting,might,contribute,schizophrenia,symptoms,represent,unexplored,target,antipsychotic,"cannabidiol.
",timing,immunosuppressive,combination,(PTCY),transplant,(haplo-HSCT),standardized.,schedules,immunosuppression,haplo-HSCT,509,PTCY,+3,+4,tacrolimus,(group,1;,"n = 215),",cyclosporine,(CSA),mycophenolate,mofetil,(MMF),+5,2;,"n = 170),",CSA + MMF,0,3;,n = 124).,Compared,2,"groups,",younger,(median,46,P = .02),more,received,(77%;,P,<,.01),regimen,containing,"thiotepa,","fludarabine,",busulfan,(84%;,P<,.01).,"years,",44%,"1,",48%,"2,",59%,(P=,.15);,(LFS),"43%,","46%,",53%,.05);,refined,"disease-free,",(rGRFS),"33%,","39%,",36%,(P = .02).,grade,II-IV,GVHD,25%,39%,18%,(P<,.01);,"25%,",24%,.50);,"36%,","37%,",26%,.02);,"26%,","20%,",21%,.35).,start,+1,(hazard,ratio,"[HR],",.58;,P=,.02),improved,rGRFS,"(HR,",.62;,P = .02).,outcomes,PTCY.,administered,improves,"rGRFS.
",Immune,pivotal,synucleinopathy,Parkinson’s,(PD),mediated,neurotoxic,alpha-synuclein.,limited,another,dementia,Lewy,bodies,(DLB).,Recent,impairment.,aimed,estimate,plasma,profile,synucleinopathies,(PD,"(PDD),",DLB).,Plasma,(interferon-gamma,"(IFN-gamma),",interleukin,(IL)-4,"(IL-4),","IL-6,","IL-10,",tumor,necrosis,factor,alpha,"(TNF-alpha),",monocyte,chemoattractant,protein-1,(MCP-1)).,estimated,16,"DLB,","PDD,",28,PD,individuals,disorders,(controls),Luminex,array,system.,Cognitive,assessed,Mini–Mental,State,Examination,(MMSE).,TNF-alpha,IL-6,elevated,"(DLB,",PDD),controls,IL-10,PDD,(p < 0.05).,IFN-gamma,"(p < 0.001,","p = 0.026,",respectively),DLB,(p = 0.032).,"PD,",MCP-1,(p < 0.001).,same,"time,",differences,"TNF-alpha,",found.,pronounced,"demetia.
",Many,metastatic,non-small-cell,lung,cancer,(mNSCLC),experience,first-,second-line,treatment;,options,required,"ARCTIC,",phase,"III,","randomized,",open-label,durvalumab,±,tremelimumab,versus,care,(SoC),≥,third-line,"mNSCLC.
","methods
",ARCTIC,comprised,independent,sub-studies.,Study,A:,126,≥25%,(TCs),expressing,programmed,ligand-1,(PD-L1),(1,:,[up,12,months,10 mg/kg,every,weeks,(q2w)],SoC.,B:,469,PD-L1,TC,<25%,(3 :,durvalumab +,(12,20,mg/kg +,mg/kg,q4w,then,34,10,"q2w),","SoC,",(up,24,q12w).,Primary,end,points:,(OS),progression-free,(PFS),SoC,(study,A;,descriptive,only),"B).
",11.7,(durvalumab),6.8,{hazard,(HR),0.63,[95%,confidence,interval,"(CI),",0.42–0.93]};,PFS,3.8,2.2,[HR,0.71,(95%,"CI,",0.49–1.04)].,11.5,(durvalumab +,tremelimumab),8.7,0.80,0.61–1.05);,P =,0.109].,Median,3.5,groups,0.77,0.59–1.01);,0.056].,Treatment-related,3/4,events:,9.7%,44.4%,(SoC;,A),22.0%,36.4%,heavily,pretreated,"mNSCLC,",clinically,meaningful,improvements,(patients,≥25%);,numerical,<25%).,Safety,profiles,consistent,previous,"studies.
",Trial,"registration
",Clinicaltrials.gov,identifier:,"NCT02352948.
","Objectives
",Because,reference,intervals,(RIs),biochemistry,analytes,matched,population,"defined,",joined,global,values,(RVs),coordinated,IFCC,Committee,Intervals,Decision,Limits,"(C-RIDL).
",According,C-RIDL,harmonized,"protocol,",793,healthy,volunteers,recruited,"Saint-Petersburg,","Moscow,",Yekaterinburg.,tested,analytes.,Sources,variation,RVs,explored,regression,partitioning,sex,judged,deviation,ANOVA.,Latent,abnormal,exclusion,(LAVE),applied,influence,metabolic,inappropriate,sampling,conditions.,RIs,computed,parametric,"method.
",No,appreciable,between-city,Partition,Age-related,"analytes,",especially,females.,trend,exaggerated,nutritional,closely,mass,index,"(BMI),",because,BMI,increases,prominently,age.,"Therefore,",BMI > 28 kg/m2,excluded,determining,age-specific,RIs.,LAVE,effective,lowering,"markers.
",established,biochemical,up-to-date,methods,detailed,consideration,RVs.,similar,participating,"countries.
",Adequate,transplacental,passage,maternal,thyroid,hormone,important,normal,fetal,growth,development.,Maternal,overt,hypothyroidism,hyperthyroidism,"birthweight,",knowledge,gaps,remain,subclinical,function,abnormalities,birthweight—both,general,third,trimester,pregnancy.,examine,associations,"birthweight.
",review,individual-participant,"meta-analysis,",searched,MEDLINE,"(Ovid),","Embase,",Web,"Science,",Cochrane,Central,Register,Controlled,"Trials,",Google,Scholar,inception,Oct,"15,","2019,",prospective,pregnancy,issued,invitations,identify,authors,join,Consortium,Thyroid,Pregnancy.,"pregnancies,",in-vitro,"fertilisation,",pre-existing,medication,"usage,","miscarriages,",stillbirths.,main,(SGA),"neonates,",large,newborn,birthweight.,analysed,mixed-effects,models,adjusting,"BMI,","ethnicity,","parity,","sampling,","sex,",birth.,pre-registered,International,Prospective,Systematic,"Reviews,","CRD42016043496.
","Findings
",2526,published,"reports,",36,cohorts,met,inclusion,criteria.,15,agreed,"participate,",five,unpublished,datasets,"added,",giving,48 145,mother–child,pairs,"exclusions,",whom,1275,(3·1%),(increased,stimulating,[TSH],free,thyroxine,[FT4]),929,(2·2%),isolated,hypothyroxinaemia,(decreased,FT4,TSH).,higher,SGA,euthyroidism,(11·8%,vs,10·0%;,adjusted,difference,"2·43%,",95%,CI,0·43,4·81;,odds,[OR],"1·24,",1·04,1·48;,p=0·015),mean,birthweight,(mean,−38,"g,",−61,−15;,"p=0·0015),",measurement,second.,Isolated,(7·3%,"10·0%,","−2·91,",−4·49,−0·88;,OR,"0·70,",0·55,0·91;,p=0·0073),45,73;,p=0·0012).,Each,SD,TSH,6,g,(–10,−2;,"p=0·0030),",estimates,women,peroxidase,negative,(pinteraction=0·10).,(–25,−17;,"p<0·0001),","second.
","Interpretation
","inverse,",dose-response,(even,within,range),advance,understanding,complex,relationships,"outcomes,",prompt,careful,risks,benefits,levothyroxine,"pregnancy.
","Funding
",Netherlands,Organization,Scientific,Research,(grant,"401.16.020).
",Lorlatinib,third-generation,tyrosine-kinases,inhibitor,(TKI),targeting,ALK/ROS1,fusions.,FDA,approved,lorlatinib,TKI-pretreated,ALK(+),"NSCLC,",approval,ROS1(+),pending.,largest,real-world,NSCLC,harboring,rearrangements,"lorlatinib.
",123,enrolled,retrospectively,(data,cut-off,1/1/2019).,program,therapy.,Outcome,defined,investigator,upon,RECIST,1.1,"criteria.
",106,8,countries.,included,"males,",73,never-smokers,metastases.,Extracranial,(EC),intracranial,(IC),rates,(RR),60,62,"%,",control,(DCR),91,88,Mean,(DoT),23.9 ± 1.6,(mOS),89.1 ± 19.6,ROS1,53,65,EC,IC,RR,67,DCR,92,78,DoT,18.1 ± 2.5,mOS,90.3 ± 24.4,significantly,line,parameters.,events,edema,(48,hyperlipidemia,(47,weight,gain,(25,fatigue,%).,CNS,1–2,"patients.
",shows,outstanding,EC/IC,ALK/ROS1(+),NSCLC.,89 ± 19,supports,90 ± 24,unprecedented,"NSCLC.
",Diabetes,mellitus,dysregulation,complications.,50%,diabetes,suffer,diabetic,"polyneuropathy,",involves,presence,nerve,dysfunction,symptoms.,new,synthetic,arginine-rich,exendin-4,(Peptide,D),complications,caused,"diabetes,","neuropathy,",induced,administering,streptozotocin,(STZ).,Three,Peptide,D,"(0.1,",10 μg/kg).,Byetta®,(1 μg/kg),80,days.,Neuropathic,pain,tactile,allodynia.,STZ-treated,showed,allodynia,unlike,naïve,animals.,histological,diameter,sciatic,fibers,smaller,IHC,myelin,(MBP),Byetta®.,resulted,MBP,myelinated,fibers.,poly-arginine,peptides,promising,"polyneuropathies.
",pattern,auditory,preterm,children,"birth.
","design
",longitudinal,"study.
",involved,271,aged,old.,Children,divided,groups:,70,birth,32–36,(Group,201,22–31,2).,Hearing,"ABR,","ASSR,","OAE,",behavioral,"audiometry,",pure,tone,audiometry.,"Additionally,",some,"children,","CT,","MRI,",GBJ2,evaluations,performed.,Assessments,hearing,3–4,times,year,under,age;,2–3,5,over,Infants,problems,examined,"life,",annual,examinations,"aged.
",SNHL,ANSD,(25.7%),64,(31.8%),Group,occurrence,assessment,(p > 0.05).,Further,children:,child,1.,Four,kinds,noted:,recovery,ANSD;,loss;,transformation,"SNHL,",vice,versa.,"factors,",discussed,"article.
",prematurely,born,tends,"unstable,","infants,",deteriorate,improve.,before,weeks’,gestation,require,least,until,Caution,advised,cochlear,implantation,32,"age.
","Introduction
","II,",single-arm,ASCEND-3,ceritinib,anaplastic,lymphoma,kinase,(ALK),(ALKi)–naive,ALK-rearranged,lines,chemotherapy.,"Here,",final,"results.
",Eligible,(including,asymptomatic,neurologically,stable,metastases),oral,(750,"mg/day,",fasted).,primary,investigator-assessed,(ORR).,Secondary,points,Blinded,Independent,Committee–assessed,ORR;,investigator-,"rate,","response,",(PFS);,(OS);,safety.,Exploratory,patient-reported,"outcomes.
",Of,124,"enrolled,",(98.4%),antineoplastic,medications,(31,[25.0%],"regimens),",49,(39.5%),baseline,cutoff:,January,"22,",2018),52.1,"(range,",48.4–60.1),ORR,67.7%,[CI]:,"58.8–75.9),",16.6,CI:,11.0–23.2).,51.3,42.7–55.3).,(all,"grades,",≥60%,all-causality),diarrhea,"(85.5%),",nausea,"(78.2%),",vomiting,(71.8%).,(14.5%),event,discontinuation.,Health-related,quality,maintained,"treatment.
",Ceritinib,prolonged,"OS,","PFS,",chemotherapy-pretreated,(at,"lines),",ALKi-naive,ALK+,possibilities,angioprotection,osteonecrosis,given,bisphosphonates.,"experiment,",27,injected,saline;,zoledronic,acid,weeks;,"weeks,",added,doses,sulodexide,weeks.,After,constructed,teeth,extracted.,velocity,linear,periodontal,area,extracted,tooth,laser,high-frequency,Doppler,ultrasound,(with,vasoactive,substance,acetylcholine,3%,1min).,structure,bony,tissues,head,"tomography,",saline,microcirculation,use,acid.,mucous,membranes,"and,",greater,"extent,",tissue.,Zoledronic,causes,periosteal,"disorders,",includes,cellular,component,(impaired,endothelium-dependent,vasodilation,membrane,vessels),reducing,tissues.,"Sulodexide,","however,",restoration,reduces,"osteonecrosis.
",subcortical,pathways,motor,spinal,cord,injury,(SCI),animal,models.,descending,interlimb,lumbosacral,excitability,SCI,"humans.
",Ulnar,transcutaneous,electrical,condition-test,paradigm,connections,linking,cervical,segments,non-injured,(n=15),injured,(n=18),"participants.
",Potentiation,spinally,evoked,responses,(sEMRs),ulnar,7/7,volitional,leg,muscle,"activation,",6/11,activation.,"six,",sEMRs,rostral,innervation,entry,"zones.
",Descending,modulation,pools,via,projections,exist,despite,absence,"activation.
","Significance
",Evaluation,"sub-clinical,",spared,residual,"function,",plasticity,"rehabilitation..
",Macrophages,participate,regulation,morphogenetic,placenta.,roles,unclear,placental,macrophages,(Hofbauer,cells).,characterize,steps,production,(intracellular,synthesis,secretion),compare,secretory,villous,"tissue.
",tissue,placentas,pregnancies,9–12,38–40,gestation.,Intracellular,determined,cytometry,antibodies.,Secreted,quantified,cytometric,bead,"ELISA.
",Two,patterns,macrophages.,Cytokines,"(IL-1,","IL-8,",TNFα),basal,stimulated,endotoxin.,"(IL-11,","IL-17A,","IL-17F,","TGF-β,",VEGF),constitutive,did,respond,stimulation.,age-dependent,observed:,secretion,TNFα,IL-8,IL-11,IL-17,third-trimester,first-trimester,cells.,Comparison,suggested,intraplacental,extraplacental,"production.
","Discussion
",would,safe,assume,"production,",correspond,macrophages:,“immune”,“morphogenetic”.,attenuated,supposedly,local,"levels,",confined,Mutations,glucocerebrosidase,(GBA),cause,Gaucher,"(GD),",lysosomal,storage,disorder,"(LSD),",Parkinson's,(PD).,Lysosome,functionality,plays,extracellular,vesicles,(EVs),content.,EVs,GD,terms,"amounts,","distribution,",cargo.,sequential,centrifugation,сryo-electron,microscopy,"(cryo-EM),",nanoparticle,tracking,"(NTA),",light,scattering,(DLS).,exosomal,HSP70,tetrasponins,cytometry.,Protein,profiling,mass-spectrometry,(shotgun,analysis).,morphology,exosomes,derived,cryo-EM,DLS,"(р<0.0001,","p < 0.001,",confirmed,mode,NTA,(p < 0.02).,Cryo-EM,double,multilayer,enriched,surface,"(CD9,","СD63,",CD81),exosome-associated,Proteomic,proteins,pathogenesis.,"Thus,",striking,alteration,"morphology.
",perform,postural,neuropsychiatric,tremor,"(ET),","phenotypes,",combined,ET,"(ET-PD).
",169,(1.0–2.0),111,advanced,(2.5–3.0),Hoehn,Yahr,"scale,",26,ET-PD,study.,Motor,non-motor,standardized,scales,"stabilometry.
",ETPD,milder,parkinsonism,posture,walking,scales.,"ETPD,",PD.,Using,"stabilometry,",discovered,indexes,stabilometric,parameters,although,"ET.
",conducted,helpful,differential,diagnosis.,helps,expand,"ET-PD.
",recent,highlighted,autophagy,pathway,(ALP),Genes,GBA,"LRRK2,",harbor,mutations,ALP.,"α-synuclein,",encoded,SNCA,"gene,",degraded,mainly,"ALP,",mutations/multiplications,chaperone,ALP,functions.,PD-related,"genes,","PRKN,","PINK1,","TMEM175,","SMPD1,","CTSD,",CTSB,"more,",Understanding,relationship,crucial,uncovering,long-awaited,neuroprotective,therapies.,"review,",will,"(other,",atypical,forms,"Parkinsonism,",review).,genes,"proteins,","PD.
",elucidate,dynamical,complexity,impulse,sensory,neurons,emergence,antinociceptive,painful,stimulus.,solve,problem,bifurcation,enabled,us,relations,nociceptive,neuron,effect.,shown,mechanism,suppression,ectopic,bursting,discharges,base,neurons.,Under,potassium,"blocking,",connected,entirely,modification,activation,gating,NaV1.8,sodium,channels,action,comenic,non-opioid,analgesic,anoceptin.,explain,neuropathic,"pain.
",Metoclopramide,widely,abortive,migraine,advantage,having,"antiemetic,",properties.,metoclopramide,"migraine,",anti-cephalalgic,elucidated.,Taking,account,key,trigeminovascular,"pathophysiology,",investigate,neurogenic,dural,valid,electrophysiological,neurovascular,nociception.,Extracellular,recordings,second-order,dura-sensitive,trigeminocervical,(TCC),anaesthetised,Cumulative,infusion,(three,30 min,"intervals,",5 mg/kg,i.v.,"step,",n = 8),dose-dependently,suppressed,firing,TCC,"stimulation,",maximally,30%[0–49%],(median[Q1-Q3]),4%[0–30%],"level,",respectively,(both,"p = 0.001,",(n = 8)).,By,"contrast,",separate,cumulative,(5 mg/kg,n = 6),vehicle,(n = 6),p > 0.05).,unable,does,suppress,anti-migraine,action.,here,neurophysiological,therapeutic,"migraine.
",Exposure,lipopolysaccharidein,affects,disturbances,potentiation,functions,"rats,
",Intranasal,disrupts,metabolism,"hippocampus,
","diseases,
",immunoassay,"pathogens,
",Biological,dynamics,simulation,"C60[C(COOH)2]3,
",checkpoints,predictor,"syndrome,
",Guidelines,TMS/tES,"pandemic,
",sclerosis:,"onset,
",Eight-year,"maculopathy,
",Haploidentical,Post-Transplantation,Cyclophosphamide,Cell,Acute,Lymphoblastic,Leukemia:,Report,European,Society,Blood,Marrow,Leukemia,Working,"Party,
",Design,drinkers,daily,"Russia,
",Mast,degranulation,release,influenza-sensitized,"mice,
",Altered,reversed,peripubertal,"treatment,
",Timing,Transplantation:,Comparative,Behalf,Party,"Transplantation,
",synucleinophaties,"dementia,
",ARCTIC:,"cancer☆,
",Establishing,major,population:,part,"values,
",Association,birthweight:,"meta-analysis,
",GLASS:,Global,Study:,real,"patients,
",Therapeutic,exenatide,neuropathy,Changes,premature,"study,
",Final,Overall,Survival,Other,Efficacy,Results,From,ASCEND-3:,Phase,II,of Ceritinib,ALKi-Naive,ALK-Rearranged,"NSCLC,
",Disorders,bisphosphonate,osteonecrosis:,Interlimb,"injury,
","macrophages,
","disease,
",Postural,instability,disturbance,overlapping,"Disease,
",Autophagy,disease;,"genetics,
",Mechanisms,"emergence,
",Influence,Trigeminovascular,Nociception:,Possible,Anti-migraine,Mechanism,"Action,
"
ВСТРЕТИЛОСЬ_РАЗ_в_2020,30,1,229,1,2,20,4,6,332,4,367,5,317,1,1,3,4,9,7,2,37,12,4,1,3,3,3,3,1,18,4,33,3,4,11,13,3,1,9,3,83,2,2,1,3,4,2,2,1,13,4,4,22,2,10,1,1,1,1,1,2,1,35,1,1,1,2,2,4,20,1,3,4,6,68,1,1,1,3,27,1,13,2,2,7,1,1,1,2,2,1,76,9,6,1,1,1,7,1,56,1,12,2,4,1,1,5,2,1,2,6,1,1,1,1,1,1,3,45,7,8,5,1,2,1,4,12,1,1,2,1,2,2,6,7,1,1,1,1,1,5,123,2,1,15,3,1,7,3,1,4,1,4,1,3,31,3,22,16,5,1,7,1,1,5,1,5,16,24,85,1,2,3,1,1,1,1,1,10,3,3,3,1,2,2,1,8,1,6,1,2,1,1,8,3,17,2,1,7,1,3,9,2,2,1,2,1,1,1,137,1,1,2,1,11,12,1,4,1,1,6,1,7,1,2,1,1,1,1,1,1,1,3,1,2,2,1,1,5,3,6,8,1,1,14,2,2,1,7,1,1,1,1,1,1,25,4,2,1,1,1,1,1,1,2,1,1,5,1,1,3,2,17,1,1,1,2,2,13,4,1,1,5,8,2,5,4,2,2,1,1,1,8,2,1,1,2,3,3,2,1,1,2,1,1,2,5,6,2,20,8,1,2,1,1,7,1,1,2,1,4,1,1,3,1,9,4,1,2,1,3,1,1,1,2,1,3,7,1,1,1,1,1,2,11,1,1,14,1,1,4,5,1,1,8,1,1,15,1,5,2,2,3,4,1,2,2,4,1,1,1,1,1,1,1,1,2,3,1,1,1,2,1,5,4,1,1,1,1,2,3,3,1,1,1,2,3,1,1,12,1,4,1,1,2,1,3,3,10,1,1,1,2,1,1,1,3,1,1,1,1,1,1,1,2,1,6,1,10,3,1,3,1,2,1,3,2,1,1,7,1,4,1,2,6,3,1,1,1,2,1,2,1,1,2,1,1,1,1,1,2,1,1,1,1,3,2,1,1,2,1,3,1,1,7,5,2,2,1,1,11,1,1,1,1,2,1,1,1,1,1,1,1,4,1,2,1,1,3,1,1,1,1,3,1,1,7,1,1,3,1,1,1,1,1,2,1,2,2,2,1,2,1,1,1,1,7,1,1,1,1,1,1,1,1,1,1,1,1,1,7,1,1,1,1,1,1,6,1,5,1,1,2,3,2,1,1,1,4,5,1,1,6,1,1,1,1,8,1,2,4,1,13,5,6,3,5,5,2,3,55,2,2,1,1,1,2,8,2,2,7,1,1,1,1,2,1,2,1,2,1,2,1,1,1,1,6,3,8,3,13,1,1,1,2,1,1,1,1,1,1,2,8,4,1,1,2,1,5,1,1,2,1,2,4,1,2,14,4,1,1,1,5,19,9,1,3,1,1,1,1,10,2,1,1,1,4,2,1,1,6,1,4,1,1,3,13,1,4,9,4,1,1,1,3,1,3,5,1,1,1,4,2,1,3,1,2,1,1,1,1,1,3,9,1,3,3,4,1,1,1,1,1,1,1,2,1,1,1,1,4,1,1,1,2,1,3,6,1,1,2,2,3,4,4,1,3,1,1,3,4,1,3,1,4,1,2,1,1,4,1,2,3,1,1,1,1,2,1,1,1,11,1,2,1,1,1,2,1,1,1,4,1,2,5,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,10,4,3,8,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,7,1,1,1,1,1,1,1,1,3,2,2,1,3,1,1,1,1,1,1,1,1,1,2,1,1,2,1,7,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,1,3,4,2,2,7,2,1,2,1,3,5,5,2,7,9,1,1,1,2,3,1,1,3,5,5,1,1,1,1,1,3,1,5,2,1,1,1,1,1,1,1,1,2,1,1,1,1,4,4,1,1,2,4,1,1,1,1,3,1,2,1,1,1,19,1,1,2,11,3,1,1,5,1,1,1,1,1,2,1,2,1,1,2,4,4,4,2,2,3,1,1,3,1,1,1,1,1,1,1,1,3,2,1,2,5,6,1,1,1,6,4,1,3,1,2,1,2,1,2,2,1,1,1,4,1,2,1,1,5,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,3,3,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,5,1,1,4,2,1,1,2,1,2,1,2,1,2,1,1,1,4,1,1,1,2,1,1,2,1,1,1,1,3,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,5,2,1,2,1,2,3,2,1,1,1,1,1,3,1,1,1,1,1,1,2,3,2,1,1,1,6,4,1,1,1,1,2,2,1,2,1,1,1,2,1,2,1,6,1,1,2,1,1,1,1,2,1,1,2,1,1,3,2,1,1,1,9,4,2,2,1,5,2,1,1,3,2,2,1,1,1,4,1,1,4,3,1,2,2,3,1,2,5,2,1,1,2,1,1,1,1,5,7,3,2,3,1,1,1,1,3,8,1,1,1,1,4,1,1,1,1,5,2,2,2,2,3,1,2,5,1,4,1,1,1,1,8,1,1,2,3,1,2,1,2,1,1,2,1,1,4,1,2,1,1,4,1,1,5,1,5,1,1,1,1,1,4,8,2,4,1,2,2,1,1,3,2,1,2,1,3,7,2,2,1,2,1,5,1,1,2,1,1,1,1,1,1,1,2,1,2,1,1,1,5,3,3,2,1,1,1,1,8,1,1,1,1,3,2,1,1,1,2,2,2,2,1,1,1,1,2,3,1,2,2,1,1,1,1,5,1,1,1,1,1,1,4,15,1,1,2,2,1,1,1,3,5,1,2,1,1,1,1,1,1,1,1,1,1,4,3,3,5,5,2,2,3,2,1,4,1,1,1,1,1,2,2,1,1,2,2,1,3,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,2,2,1,1,1,1,3,1,2,2,1,1,1,1,3,1,1,2,4,1,1,1,12,1,1,1,1,2,1,1,1,1,1,4,1,1,1,1,1,1,1,1,1,2,1,5,8,3,1,6,1,1,1,1,1,1,2,1,1,1,1,9,1,1,1,1,1,1,1,1,4,1,1,1,1,1,1,1,4,1,1,1,3,1,1,1,2,1,1,1,1,1,1,1,1,1,1,7,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,2,1,1,3,2,2,1,1,1,1,1,2,1,1,1,1,1,1,1,3,2,1,4,3,1,1,3,1,1,1,1,1,1,1,3,1,1,2,1,1,1,1,9,1,1,1,1,1,7,5,1,1,1,1,1,1,1,1,1,1,1,1,2,1,3,1,3,1,5,1,1,1,1,1,1,1,1,1,1,1,1,1,4,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,4,1,1,1,1,2,1,1,1,1,2,1,2,2,1,2,1,2,2,3,2,1,1,1,1,6,1,1,1,1,1,2,3,11,3,3,1,1,1,2,1,1,1,1,1,2,3,2,1,2,1,1,1,1,1,1,1,3,1,2,1,15,2,1,1,1,2,1,1,7,1,1,1,1,1,2,1,1,1,7,1,2,1,1,1,1,2,2,1,6,1,1,2,1,2,1,2,3,1,1,2,2,2,1,1,1,1,1,1,1,2,1,2,1,1,1,8,1,7,8,1,4,1,2,1,1,1,1,1,1,7,2,1,1,1,1,1,1,1,1,3,1,3,13,1,1,10,1,1,2,1,3,3,1,1,3,1,1,1,4,2,2,3,3,2,1,1,1,1,1,4,1,1,2,1,4,2,1,1,1,2,1,3,1,1,1,1,1,2,2,1,1,5,1,1,3,1,6,3,1,1,2,2,1,1,1,2,1,2,1,5,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,2,2,2,2,1,1,1,2,2,2,5,2,1,1,1,1,1,3,1,4,2,1,2,3,2,3,1,1,2,3,1,1,2,1,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1,2,1,2,4,1,2,1,2,1,1,1,1,1,1,1,1,2,2,1,1,1,5,2,1,1,3,1,1,1,1,2,2,1,1,1,2,1,1,1,1,2,1,2,1,4,1,1,2,1,2,1,1,1,1,1,1,2,1,1,1,2,1,1,1,1,1,1,1,8,10,2,3,6,3,1,1,3,1,4,1,3,1,1,2,4,9,1,1,1,3,3,2,1,1,1,2,3,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,3,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,3,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,3,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,4,3,1,3,1,7,4,2,1,2,1,2,7,1,1,1,1,1,1,1,1,1,1,1,2,4,2,1,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,2,2,2,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,2,1,1,3,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,4,1,1,2,1,1,2,1,1,1,1,1,5,1,1,4,1,1,1,4,1,1,1,2,3,1,2,1,1,1,1,1,1,1,1,1,1,1,1,3,1,2,2,1,2,3,1,1,2,1,2,1,1,2,1,3,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,2,1,3,1,3,1,1,4,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,1,1,1,1,2,2,1,1,1,1,1,5,1,1,3,7,3,1,2,1,2,1,1,1,1,1,1,1,1,1,1,1,1,4,4,1,1,2,1,1,1,1,1,3,2,2,3,1,1,3,3,1,2,3,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,4,3,13,1,1,1,1,1,1,1,1,1,2,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,7,2,4,4,2,2,2,2,1,2,1,1,1,1,1,1,1,2,1,1,1,7,1,2,1,1,2,1,1,1,1,1,3,1,1,1,1,1,1,1,2,1,1,3,1,1,1,1,1,3,1,4,1,4,1,1,1,1,1,1,1,2,1,1,1,3,1,1,1,1,1,1,2,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,2,2,2,2,1,1,2,3,1,1,1,1,1,1,2,1,1,1,1,2,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,4,5,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,3,1,1,1,2,4,1,1,4,3,1,1,1,1,1,1,1,1,1,2,1,1,1,3,1,1,1,1,1,1,1,1,1,1,3,6,6,4,2,2,1,1,1,3,4,2,5,1,1,1,2,1,1,1,2,1,1,1,1,1,1,1,1,2,2,3,1,2,1,3,2,2,2,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,5,1,8,6,1,1,1,2,6,1,1,1,1,1,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,6,1,2,1,1,1,2,1,1,1,1,1,1,1,1,2,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,4,1,1,1,4,2,1,1,1,1,2,1,1,4,5,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,2,1,1,1,2,1,1,1,1,4,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,2,1,1,1,1,2,2,2,1,1,1,6,1,1,1,1,3,1,1,1,1,1,3,1,1,1,2,2,1,3,1,1,1,1,1,1,1,1,1,1,2,2,2,1,1,2,1,2,1,1,1,1,1,1,2,2,1,1,1,1,1,1,2,1,1,2,1,1,1,2,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,3,1,1,1,3,3,1,2,5,2,3,1,1,1,1,1,1,1,1,2,1,1,1,5,3,1,1,2,1,1,1,1,1,1,2,1,2,1,1,1,1,2,1,1,3,1,1,1,1,2,1,1,2,1,1,1,1,6,1,1,1,1,1,1,4,1,1,2,3,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,2,1,3,1,1,1,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1
